$1.30
-0.07 (-5.11%)
Open$1.35
Previous Close$1.37
Day High$1.35
Day Low$1.25
52W High$3.22
52W Low$0.91
Volume—
Avg Volume139.9K
Market Cap61.78M
P/E Ratio—
EPS$-0.25
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,251.5% upside
Current
$1.30
$1.30
Target
$43.57
$43.57
$34.30
$43.57 avg
$49.66
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 42.8K | 62.3K | 9.20M |
| Net Income | -11,766,291 | -15,432,325 | -2,830,498 |
| Profit Margin | -27,235.7% | -25,873.9% | -30.8% |
| EBITDA | -11,828,068 | -16,375,203 | -2,581,372 |
| Free Cash Flow | — | — | -3,568,526 |
| Rev Growth | -31.4% | -31.4% | +9.2% |
| Debt/Equity | — | — | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |